Phaseline

Companies › Imugene

Imugene: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Azer-cel (PBCAR0191)
Allogeneic anti-CD19 CAR-T cell therapy
CD19Phase 1Non-Hodgkin LymphomaJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03666000Azer-cel (PBCAR0191)Phase 1Non-Hodgkin LymphomaOncologyJun 2027

Targets

CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.